Vijay Patel, MD
Internal Medicine · Matawan, NJNPI 1922045590
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,460 of the $1,766 with a category attached, or 82.7%. It is spread thinly across 20 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $479 and has fallen 77.0% since, to $110 in 2025.
Across 106 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$366
- Welch Allyn$242
- Novo Nordisk$214
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$131
- Boehringer Ingelheim$120
- Amgen$117
- plus $577 from 14 others
Across 7 payments — averaging $17,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Celltrion, Inc.$70K
- Takeda Pharmaceuticals U.S.A., Inc.$31K
- Genentech, Inc.$18K
What the payments were for
- Food & beverage$1,46083%
- Education$654%
- Gifts$24214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $366 |
| Welch Allyn | 1 | $242 |
| Novo Nordisk | 14 | $214 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $131 |
| Boehringer Ingelheim | 9 | $120 |
| Amgen | 8 | $117 |
| Merck | 6 | $91 |
| Novartis | 6 | $84 |
| Sanofi-aventis U.S. LLC | 6 | $78 |
| GSK | 4 | $60 |
| Bayer | 3 | $59 |
| Exact Sciences | 2 | $44 |
| Johnson & Johnson | 3 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Pfizer | 1 | $14 |
| Abbott | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABPM 7100 Ambulatory Blood Pressure Monitor$242
How this compares
$1,766 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 236 | $254,335 |
| JanuviaSitagliptin Phosphate | 254 | $250,309 |
| OzempicSemaglutide | 186 | $214,293 |
| Tolvaptan | 20 | $184,961 |
| JardianceEmpagliflozin | 181 | $182,353 |
| TradjentaLinagliptin | 136 | $121,320 |
| EliquisApixaban | 127 | $113,075 |
| JanumetSitagliptin Phos/Metformin Hcl | 99 | $81,519 |
| Advair HfaFluticasone Propion/Salmeterol | 163 | $63,550 |
| EntrestoSacubitril/Valsartan | 47 | $53,940 |
| Bydureon BciseExenatide Microspheres | 39 | $47,429 |
| RybelsusSemaglutide | 28 | $45,006 |
| LinzessLinaclotide | 41 | $44,040 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $41,648 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $37,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $91 | $331,829353 claims |
| Boehringer IngelheimJardiance, Tradjenta | $120 | $303,673317 claims |
| AstraZenecaFarxiga, Lokelma, Symbicort | $366 | $302,488306 claims |
| Novo NordiskOzempic, Rybelsus | $214 | $259,299214 claims |
| PfizerEliquis | $14 | $113,075127 claims |
| AbbVieLinzess, Restasis | $14 | $57,60767 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $60 | $54,02475 claims |
| NovartisEntresto | $84 | $53,94047 claims |
| AmgenProlia | $117 | $25,81716 claims |
| Johnson & JohnsonXarelto | $42 | $17,43420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Matawan
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.